FDA asks for more time to evaluate Onglyza for approval

04/24/2009 | Reuters

The FDA delayed by three months its approval decision on Onglyza, an experimental diabetes drug from AstraZeneca and Bristol-Myers Squibb. The agency said it needs more time to review Onglyza, although a spokesman for Bristol-Myers said he was not aware of any request from the agency for additional data on the product.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ